Trial Profile

Efficacy and Safety of Low-dose Radiation Combined With Neoadjuvant Chemotherapy and Immunotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tislelizumab (Primary) ; Carboplatin; Cisplatin; Paclitaxel
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

12 Feb 2025 Number of treatment arms are increased from 1 to 3 by the addition of Experimental: 6Gy/3f group and Experimental: 8Gy/4f group. Study design is changed from Single Group Assignment to Randomized, parallel.
12 Feb 2025 Planned primary completion date changed from 30 Jan 2025 to 30 Jun 2025.
15 Dec 2023 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com